Spirometry Protocol and Software Training Handout

Total Page:16

File Type:pdf, Size:1020Kb

Spirometry Protocol and Software Training Handout SPIROMETRY PROTOCOL AND SOFTWARE TRAINING HANDOUT Spirometry Protocol Key Points in Performing Spirometry ▪ Always demonstrate the maneuver ▪ Prompt the participant to BLAST out the air ▪ Continue by having the participant PUSH out the air ▪ Continue until the balloon bursts or at least six seconds Getting ready to do Spirometry Subjects will be instructed to not use any bronchodilator medicines for at least 4 hours prior to the appointment (in the case of salmeterol [Serevent] or Fomoterol (foradil)or Tritoprium (Spiriva) avoid for 12 hours prior to the test). Bronchodilator medicines include: Short acting bronchodilators Albuterol (ventolin, proventil, airet, volmax tablet) Levalbuterol (xopenex) Metaproterenol (alupent) Pirbuterol (maxair) Terbutaline (brethaire, brethine, bricanyl) Isoetharine (bronkosol) Ipratropium (atrovent) Ipratropium and albuterol combination (Combivent) Isoproteranol (isuprel) Primatine 1 CHW Educational Protocols – Spirometry Protocol and Software Training Handout Bitolterol (tornalate) Long acting bronchodilator Salmeterol (serevent) Fomoterol (foradil) Tritoprium (Spiriva) Bronchodilators should be avoided because they can affect the spirometry results. If the patient is having symptoms from asthma and needs to use the medicine, ask that the medicine be used 4 hours before the visit, so that the next dose is due during the visit. Patients can then do the spirometry and then the patient can take the medicine after the test is completed. When scheduling the follow-up spirometry visit, if at all possible, try to make the visit at the same time as the initial baseline visit. 1. Preparing the Computer 1. Check to see if the time and date on the lower right hand corner is current. If the date and time is NOT, the spirometer will NOT sync with the computer or the Easy One software. a. If the date and time is not current, shut down the computer. Start up the computer again and as soon as the DELL screen comes on, press key F2. b. In the upper left hand corner is the Time: And Date: change both of those boxes to the current date and time. Note that the time is in military time. 2. Put the USB end of the spirometer cable into the back of the computer. You will hear a ding. 3. Put the large end of the cable into the bottom of the hand held spirometer. The curved edge of the large cord end with the prongs facing forward; is inserted into the bottom of the spirometer unit. 4. Go to the computer and double click on the EasyWare Icon. 5. Turn the Spirometer on. 6. The EasyWare screen with participant a list of participant tests will appear. 2 CHW Educational Protocols – Spirometry Protocol and Software Training Handout If everything is connected correctly, the EasyOne page will show in the lower right hand corner, “Device Connected”. 2. Preparing the Spirometer and Computer 1. Put a Spirette into the hand held spirometer. The arrows will line up between the spirometer and the Spirette. 2. Return to the computer, Go to the EDIT menu and select New Patient. 3 CHW Educational Protocols – Spirometry Protocol and Software Training Handout 3. Enter the participant data from the participant file. The ID number is the number that is assigned to the participant and is located on the tab of the file. The number is written on the tab of the file folder. You will need to enter the DOB, your initials, height and weight, gender, asthma diagnosis, ethnicity and if they are a smoker. All of this information is available in the participant file. 4. Click on OK. 5. You will see the participant record on the top line of the table. Highlight the row with the participant data. 6. Go to the “On-line” icon. This is the first icon on the second tool bar and is located beneath the File menu. This is what connects the computer to the spirometer. 4 CHW Educational Protocols – Spirometry Protocol and Software Training Handout 7. The test page will show. It will be blank. 8. Go to the “Incentives for FVC” drop down menu. This is on the right hand side of the form, just above the “On-Line Mode” box. 9. Select “Children Balloon. swf” from the drop down list. The child with the balloon will appear on the right hand side of the screen. 10. The program is now ready with the animated incentive showing 5 CHW Educational Protocols – Spirometry Protocol and Software Training Handout 11. Go to the hand held spirometer. The screen will say Perform Test. 12. Press “Enter.” 13. The next screen on the spirometer will say “Select Test”. Use the right arrow to move the black highlight to “RECALL.” 14. Press “Enter.” 6 CHW Educational Protocols – Spirometry Protocol and Software Training Handout 15. The next screen will say “Search Test.” 16. Make sure “Last Test” is highlighted. 17. Press “Enter” 18. The screen will have the current participant’s information that you entered into the computer. 19. Press “Enter.” 7 CHW Educational Protocols – Spirometry Protocol and Software Training Handout 20. This screen with have “test” written down the side of the screen and the top of the screen will say “FVC Expiration.” 21. Press “Enter.” 22. The next screen is the “Baseline Setting.” The screen will ask to block the Spirette until prompted to blast out. 23. Have the participant place his/her hand over the end of the Spirette and blow gently. 24. Press “Enter”. 8 CHW Educational Protocols – Spirometry Protocol and Software Training Handout 25. The test screen will appear. 26. While the patient is performing the test, the 27. Here is the first completed test displayed. The balloon animation will inflate as a visual program will order the tests according to best reference of the patient’s progress. results. After three successful tests are completed, click the square box at the bottom of the screen to save the results and return to the main screen. 9 CHW Educational Protocols – Spirometry Protocol and Software Training Handout 28. The patient record has now changed to a data file that can be accessed to view test results. 29. In order to review the patient’s results, double click on the patient record and the test results screen will appear. 4. Preparing the Participant The subjects should be seated during spirometry testing. The mouthpiece of the spirometer should comfortably fit in the mouth of the test subject without undue effort. Tight fitting belts or garments should be loosened, and loose fitting dentures, oral appliances, chewing gum, candy and other foreign bodies should be removed from the test subject’s mouth. 10 CHW Educational Protocols – Spirometry Protocol and Software Training Handout 5. Explain and Demonstrate the Maneuver The maneuver should be briefly explained to the participant in words that he/she will understand: “I want you to take as deep a breath as you can and blast it out as fast and as hard as possible until no more air comes out. It is like trying to blow out all of your birthday candles.” Effort and time can be saved by giving a demonstration of the maneuver by pretending you use the spirometer. This should be done in all cases. Take a deep breath with participant’s mouth wide open, elevate participant’s shoulders, stick out participant’s tongue, lay the mouthpiece on it, close participant’s mouth around the mouthpiece, and forcefully blast out through the mouthpiece, continuing to blow for at least 6 seconds. Use enough body language to demonstrate that it must be a forceful and prolonged effort. 6. Perform the Test The subject should now perform the test. The words used to coach the subject should be expressive. Before the forced expiration, coach the subject to take as big a breath as possible—“FILL it up. More, More, More.” Have them inset the mouthpiece in their mouth and tell them to BLAST out all of your air!!!” Continue to coach the effort for a minimum of six seconds or until the flow falls to zero. During exhalation, use phrases like “Push, push, push. .” or “Squeeze” to motivate the subject. 1. The computer screen will show the child blow up the balloon and record the results. 2. You will see the results on the spirometer. 3. Select “Enter”. 4. Testing screen will show. NEXT will be highlighted in black. 5. Select “Enter” for next test. 6. Repeat blowing three times. 7. After the 3rd time, use the arrow to move over to the quit. 8. Select “Quit” 9. You will be at the “testing” screen. 10. Go to the computer screen and click on the square button. This will synchronize the spirometer results with the computer. 7. When is a Testing Session Done? 11 CHW Educational Protocols – Spirometry Protocol and Software Training Handout The goal of the testing session is to obtain three good quality or “good effort” maneuvers this will be a “C” or better. Acceptable maneuvers are those that have a rapid onset of maximum flow, that are smooth, without hesitation or coughing, and that continue until the flow rate is zero and have a minimum expiratory time of 6 seconds. If all of these criteria are met, the display will say, ‘good effort, do next effort’. No more than eight maneuvers are allowed in a single session. Experience has shown that the likelihood of improving the quality of the session is slight and the likelihood of fatiguing and frustrating the test subject (and the technician!) increases with more than eight maneuvers. If this happens, document on the participant allergy form that you were unable to do this test and identify the reason. 8. If Participant Make a Mistake Spirometry sessions will not always be perfect,.
Recommended publications
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • WO 2014/141069 Al 18 September 2014 (18.09.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/141069 Al 18 September 2014 (18.09.2014) P O P C T (51) International Patent Classification: Novartis Pharmaceuticals Corporation, 150 Industrial A61K 9/00 (2006.01) A61K 31/00 (2006.01) Road, San Carlos, California 94070 (US). A61K 9/16 (2006.01) (74) Agent: MAZZA, Michael; Novartis Vaccines and Dia (21) International Application Number: gnostics, Inc., 4560 Horton Street, Emeryville, California PCT/IB2014/059632 94608 (US). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 11 March 2014 ( 11.03.2014) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (25) Filing Language: English BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (26) Publication Language: English DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (30) Priority Data: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 61/784,865 14 March 2013 (14.03.2013) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (71) Applicant (for all designated States except US) : NO¬ OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, VARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (CH).
    [Show full text]
  • For the Durable Medical Equipment Regional Contractors (Dmercs) Initiated a Revision to the Local Coverage Determination (LCD) for Nebulizers
    AMERICAN ASSOCIATION FOR HOMECARE Via Hand Delivery January 19, 2007 Leslie V. Norwalk, Esq. Acting Administrator Centers for Medicare & Medicaid Services U.S. Department of Health and Human Services Room 445-G, Hubert H. Humphrey Building 200 Independence Avenue, SW Washington, DC 20201 http://www.cms.hhs.gov/eRulemaking Re: National Coverage Analysis for Nebulized Beta Adrenergic Therapy for Lung Diseases (CAG - 00354N) Dear Ms. Norwalk: The American Association for Homecare (AAHomecare) submits the following comments on the Centers for Medicare and Medicaid Services' (CMS') national coverage analysis (NCA) for nebulized beta adrenergic agonist therapy for lung disease. AAHomecare is the only national association representing every line of service within the homecare community. AAHomecare members include home health agencies and suppliers and manufacturers of DME, prosthetics, orthotics, and supplies (collectively "DMEPOS"), rehab and assistive technologies, and pharmacies that provide infusion and inhalation drug therapies to patients in their homes. Our membership reflects a cross-section of the homecare community, including national, regional, and local providers and suppliers. AAHomecare and its members are committed to advancing the value and practice of quality health care services at home. I. BACKGROUND As you are aware, coverage for outpatient drugs under Medicare Part B is limited to a very small number of drugs. With respect to respiratory medications, Medicare covered inhalation drugs used with a nebulizer under the premise that the drug was a supply necessary to accomplish the l therapeutic objective of the nebulizer. Medicare pays for the nebulizer, the drug, and any necessary supplies. Inhalation drugs differ significantly from other outpatient drugs that are self- administered because they require an array of professional and administrative services, including delivery, education, oversight, and monitoring to ensure that the drug therapy is administered safely and effectively in the home.
    [Show full text]
  • Salmeterol Versus Slow-Release Theophylline Combined with Ketotifen in Nocturnal Asthma: a Multicentre Trial
    Eur Resplr J 1992, 5, 1197-1200 Salmeterol versus slow-release theophylline combined with ketotifen in nocturnal asthma: a multicentre trial J.F. Muir*, L. Bertin**, D Georges**, French Multicentre Study Group Salmeterol versus slow-release theophylline combined with ketotifen in nocturnal • Service de Pneumologie, Hopital de asthma: a multicentre trial. J.F. Muir, L. Bertin, D. Georges, French Multicentre Bois Guillaume, Boisguillaume, France Study Group. • • Laboratoires Glaxo, France. ABSTRACT: We wished to assess the efficacy of inhaled salmeterol (SML; 50 Correspondence: L. Bertin 1-1g b.i.d.) compared to a combination of slow-release theophylline and ketotlfen Laboratoires Glaxo p.o. (TK; T 300 mg + K 1 mg b.i.d.) for the treatment of nocturnal asthma. 43, rue Vineuse - B.P. 166-16 Ninety six patients with nocturnal asthma, (forced expiratory volume in one sec­ F-75764 Paris Cedex 16 ) ond (FEV1 60-90% of predicted value, reversibility :z:lS%, at least two noc­ France tur nal awakenings per week) were eligible for a multicentre, double-blind, double-dummy cross-over study (14-day run-in, two successive 28-day treatment Keywords: ketotifen periods), Efficacy was assessed as success/failure, success being defined as the nocturnal asthma complete disappearance of nocturnal symptoms/awakenings during the last week salmeterol of each treatment period. theophylline There was a statistically significant difference between SML and TK for this Received: January 30 1992 criterion: 46% and 39% success with SML during periods I (first 28-day pe­ Accepted after revision August 2 1992 riod) and li (following the cross-over), compared to only 15% and 26% with TK, respectively (p<O.Ol).
    [Show full text]
  • Dry Powder Inhalers Comprising a Carrier Other Than Lactose
    (19) TZZ Z T (11) EP 2 682 097 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.01.2014 Bulletin 2014/02 A61K 9/00 (2006.01) A61K 9/14 (2006.01) A61K 31/40 (2006.01) A61K 31/439 (2006.01) (2006.01) (21) Application number: 13175077.0 A61K 31/4704 (22) Date of filing: 04.07.2013 (84) Designated Contracting States: • Türkyilmaz, Ali AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 34460 Istanbul (TR) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • Mutlu, Onur PL PT RO RS SE SI SK SM TR 34460 Istanbul (TR) Designated Extension States: BA ME (74) Representative: Sevinç, Erkan Istanbul Patent & Trademark (30) Priority: 05.07.2012 TR 201207842 Consultancy Ltd. Plaza 33, Buyukdere Cad. No: 33/16 (71) Applicant: Arven Ilac Sanayi Ve Ticaret A.S. Sisli Istanbul 34460 (TR) 34381 Istanbul (TR) (72) Inventors: • Cifter, Ümit 34460 Istanbul (TR) (54) Dry Powder Inhalers Comprising A Carrier Other Than Lactose (57) This invention relates to novel pharmaceutical other obstructive airways diseases. In addition, the compositions for inhalation comprising separately, se- present invention relates to novel pharmaceutical com- quentially or together, drugs having amine in the form of position for inhalation based on combinations of long act- a dry powder in admixture with a pharmaceutically ac- ing muscarinic antagonists, long acting beta agonists, ceptable carrier, other than lactose, and its use in the short acting beta-2 agonists, corticosteroids or a combi- treatment of respiratory condition selected from asthma nation of two or more of them.
    [Show full text]
  • Pulmonary Function Test
    Preparing for Your Exam: Pulmonary Function Test What is a pulmonary function test? Pulmonary function testing measures how well you are breathing. There are different types of breathing tests that can be done during pulmonary function testing. They include spirometry, lung volumes, and diffusing capacity. Spirometry can show how much air you can breathe in and out. It also shows how fast you can breathe in and out. Lung volumes can provide further information about how your lungs are functioning. Diffusing capacity can show how well your lungs move oxygen from the lungs to the blood. There are also airway challenge tests that assist your doctor in determining the presence or absence of asthma. The results of pulmonary function testing can help your doctor find the best treatment plan for you. How do I prepare for the test? Please follow these directions when getting ready for this test. These medicines will affect the results of some of these tests and need to be stopped before the testing is done. If the medicine is not stopped before the test, we will not be able to complete the test. • Stop these inhaled medicines for 24 hours before your appointment: o Advair® (Serevent® and Flovent®) o Serevent® (Salmeterol) o Foradil® (Formoterol) o Spiriva® (tiotropium) • Stop these inhaled medicines for 6 hours before your appointment: o Atrovent® (Ipatroprium), Combivent® • Stop these inhaled medicines for 4-6 hours before your appointment: o Proventil®, Ventolin® (Albuterol), Xopenex® (Levalbuterol), Maxair® (Pirbuterol), Alupent®, Metaprel® (Metaproterenol), Brethaire®, Brethine® (Terbutaline), Tornalate® (Bitolterol), ist. • Stop these oral medicines for 8 hours before your appointment: o Volmax®, Ventolin®, Proventil®, Proventil Repetabs® (Albuterol), Metaprel® (Metaproterenol), Bricanyl®, Bethaine® (Terbutaline) • Continue to take all other medications as usual.
    [Show full text]
  • Management of Asthma in Athletes Michael G
    Journal of Athletic Training 2005;40(3):224±245 q by the National Athletic Trainers' Association, Inc www.journalofathletictraining.org National Athletic Trainers' Association Position Statement: Management of Asthma in Athletes Michael G. Miller*; John M. Weiler²; Robert Baker³; James Collins§; Gilbert D'Alonzo\ *Western Michigan University, Kalamazoo, MI; ²University of Iowa and CompleWare, Iowa City, IA; ³Michigan State University Kalamazoo Center for Medical Studies, Kalamazoo, MI; §San Diego Chargers, San Diego, CA; \Temple University School of Medicine, Philadelphia, PA Michael G. Miller, EdD, ATC, CSCS; John M. Weiler, MD; Robert Baker, MD, PhD, ATC; James Collins, ATC; and Gilbert D'Alonzo, DO, contributed to conception and design; acquisition and analysis and interpretation of the data; and drafting, critical revision, and ®nal approval of the article. Address correspondence to National Athletic Trainers' Association, Communications Department, 2952 Stemmons Freeway, Dallas, TX 75247. Objective: To present guidelines for the recognition, prophy- in supervising therapies to prevent and control asthma symp- laxis, and management of asthma that lead to improvement in toms. It is also important for the athletic trainer to recognize the quality of care certi®ed athletic trainers and other heath care when asthma is not the underlying cause for respiratory dif®- providers can offer to athletes with asthma, especially exercise- culties, so that the athlete can be evaluated and treated prop- induced asthma. erly. Background: Many athletes have dif®culty breathing during Recommendations: The recommendations contained in this or after athletic events and practices. Although a wide variety position statement describe a structured approach for the di- of conditions can predispose an athlete to breathing dif®culties, agnosis and management of asthma in an exercising popula- tion.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0302147 A1 HARTMAN Et Al
    US 20140302147A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0302147 A1 HARTMAN et al. (43) Pub. Date: Oct. 9, 2014 (54) RESPRABLEAGGLOMERATES OF POROUS Publication Classification CARRIER PARTICLES AND MICRONIZED DRUG (51) Int. Cl. A619/16 (2006.01) (71) Applicants: Michael HARTMAN, Millbrae, CA A619/00 (2006.01) (US); Thomas ETARARA, A613 L/40 (2006.01) Burlingame, CA (US); Patrick TEUNG, A613 L/4704 (2006.01) Sunnyvale, CA (US); Jeffry G WEERS, A613 L/58 (2006.01) Belmont, CA (US) (52) U.S. Cl. CPC ........... A61 K9/1617 (2013.01); A61 K3I/4704 (72) Inventors: Michael HARTMAN, Millbrae, CA (2013.01); A61 K3I/58 (2013.01); A61K 31/40 (US); Thomas ETARARA, (2013.01); A61 K9/1682 (2013.01); A61 K Burlingame, CA (US); Patrick TEUNG, 9/0075 (2013.01) Sunnyvale, CA (US); Jeffry G WEERS, USPC ............................ 424/489: 514/312: 514/171 Belmont, CA (US) (57) ABSTRACT Embodiments of the present invention provide a dry powder Assignee: composition comprising porous carrier particles associated (73) NOVARTIS AG, Basel (CH) with one, two, three or more micronized drugs or APIs wherein an ordered mixture between the micronized drug or (21) Appl. No.: 14/202,262 drugs and the carrier particle results, such that the micronized drug or drugs adhere strongly to the carrier particles forming a stable ordered mixture of respirable agglomerates. Embodi (22) Filed: Mar 10, 2014 ments of the present invention further comprise a spray-dry ing process to create the respirable agglomerates. Embodi ments of the present invention further relate to the use of the Related U.S.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,250,300 B1 Andersson Et Al
    USOO6250300B1 (12) United States Patent (10) Patent No.: US 6,250,300 B1 Andersson et al. (45) Date of Patent: Jun. 26, 2001 (54) SYSTEM FOR DISPENSING FOREIGN PATENT DOCUMENTS PHARMACEUTICALLY ACTIVE 0 069 715 6/1982 (EP). COMPOUNDS O 237 507 2/1987 (EP). O530440 6/1992 (EP). (75) Inventors: Jan Andersson, Sodra Sandby; Hans WO 90/13328 11/1990 (WO). Jägfäldt; Eva Trofast, both of Lund; WO 92/04069 3/1992 (WO). Kjell Wetterlin, Sodra Sandby, all of WO 93/17728 9/1993 (WO). (SE) OTHER PUBLICATIONS (73) Assignee: AB Astra, Sodertalje (SE) Bogaard et al., Dose-effect Relationship of Terbutaline (*) Notice: Subject to any disclaimer, the term of this Using a Multi-dose Power Inhalation System patent is extended or adjusted under 35 (Turbuhaler) ... Powder Inhalation (Rotahaler) in Asth U.S.C. 154(b) by 0 days. matics, Pharmatherapeutica 5:400-406, 1989. Tukiainen and Terho, Comparison of Inhaled Salbutamol (21) Appl. No.: 09/418,342 Powder and Aerosol in Asthmatic Patients with Low Peak Expiratory Flow Level, Eur. J. Clin. Pharmacol. (22) Filed: Oct. 14, 1999 27:645-647, 1985. Related U.S. Application Data (List continued on next page.) (62) Division of application No. 09/309,039, filed on May 10, 1999, which is a continuation of application No. 08/866,749, Primary Examiner-Glenn K. Dawson filed on May 30, 1997, now Pat. No. 5,934,273, which is a ASSistant Examiner V. Srivastava continuation of application No. 08/654,006, filed on May 29, (74) Attorney, Agent, or Firm-Fish & Richardson P.C.
    [Show full text]
  • Drug/Substance Trade Name(S)
    A B C D E F G H I J K 1 Drug/Substance Trade Name(s) Drug Class Existing Penalty Class Special Notation T1:Doping/Endangerment Level T2: Mismanagement Level Comments Methylenedioxypyrovalerone is a stimulant of the cathinone class which acts as a 3,4-methylenedioxypyprovaleroneMDPV, “bath salts” norepinephrine-dopamine reuptake inhibitor. It was first developed in the 1960s by a team at 1 A Yes A A 2 Boehringer Ingelheim. No 3 Alfentanil Alfenta Narcotic used to control pain and keep patients asleep during surgery. 1 A Yes A No A Aminoxafen, Aminorex is a weight loss stimulant drug. It was withdrawn from the market after it was found Aminorex Aminoxaphen, Apiquel, to cause pulmonary hypertension. 1 A Yes A A 4 McN-742, Menocil No Amphetamine is a potent central nervous system stimulant that is used in the treatment of Amphetamine Speed, Upper 1 A Yes A A 5 attention deficit hyperactivity disorder, narcolepsy, and obesity. No Anileridine is a synthetic analgesic drug and is a member of the piperidine class of analgesic Anileridine Leritine 1 A Yes A A 6 agents developed by Merck & Co. in the 1950s. No Dopamine promoter used to treat loss of muscle movement control caused by Parkinson's Apomorphine Apokyn, Ixense 1 A Yes A A 7 disease. No Recreational drug with euphoriant and stimulant properties. The effects produced by BZP are comparable to those produced by amphetamine. It is often claimed that BZP was originally Benzylpiperazine BZP 1 A Yes A A synthesized as a potential antihelminthic (anti-parasitic) agent for use in farm animals.
    [Show full text]
  • Additive-Containing Paints
    Europaisches Patentamt 449 M European Patent Office m) Publication number: 0190 B1 Office europeen des brevets EUROPEAN PATENT SPECIFICATION Date of publication of the patent specification : intci- C09D 7/12 09.08.89 Application number: 85116046.5 Date of filing: 16.12.85 Additive-containing paints. Priority: 03.01.85 IT 1900885 Proprietor: OECE Industrie Chimiche Spa, via Voltumo 96, 1-41032 Cavezzo (Modena)(IT) @ Date of publication of application : 13.08.86 Bulletin 86/33 Inventor: Raffaellini, Peppino, via della Liberia 20, 1-41032 Cavezzo (Modena)(IT) Inventor: Benattl, Gastone, via Gavioli 132, Publication of the grant of the patent : 1-41032 Cavezzo (Modena)(IT) Bulletin 89/32 Inventor: Vernizzi, Giorgio, via Carbonieri 47, 09.08.89 1-41100 Modena(IT) Inventor: Trevisan, Luclo, via Galimberti 9, Parma(IT) Designated Contracting States: FR GB IT LI LU NL SE AT BE CH DE Representative: Gervasl, Gemma, Dr. et al, Studio Brevetti e Marchi NOTARBARTOLO & GERVASI 33, Viale Blanca Maria, 1-20122 Milano(IT) References cited: EP-A- 0093 198 CA-A-899782 CH-A-293434 US-A-2103830 0) o Q Note- Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned fee has been paid (Art. 99(1) European patent ft statement. It shall not be deemed to have been filed until the opposition M convention). ^ ACTORUM AG EP 0190 449 B1 Description <- The present invention relates to novel paints showing a lower irritating power on the respiratory and 5 conjunctival mucosae, and improved olfactory characteristics.
    [Show full text]